Filing Details

Accession Number:
0001127602-14-002360
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-01-21 13:43:41
Reporting Period:
2014-01-16
Filing Date:
2014-01-21
Accepted Time:
2014-01-21 13:43:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1585364 Perrigo Co Plc PRGO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1242215 C Joseph Papa C/O Perrigo Company
515 Eastern Avenue
Allegan MI 49010
President And Ceo Yes Yes No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2014-01-16 5,000 $58.82 101,655 No 4 M Direct
Ordinary Shares Disposition 2014-01-16 300 $157.04 101,355 No 4 S Direct
Ordinary Shares Disposition 2014-01-16 4,700 $157.63 96,655 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Employee Stock Option Right to Buy Disposition 2014-01-16 5,000 $0.00 5,000 $58.82
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
25,183 2020-08-19 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 11, 2013. This 10b5-1 sales plan will expire on the close of business November 11, 2014.
  2. The price in column 4 is a weighted average. The prices actually received ranged from $157.08 to $158.05. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
  3. Exercisable in 3 equal annual installments beginning 8/19/2011